Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls
Genes · 17.05.2025 · 16 (5) · 592
DOI: 10.3390/genes16050592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 17.05.2025. Verfasst von Nahad Al-Mahrouqi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratories, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat 123, Oman. Hauptthemen laut MEDLINE: Neoplasms, Pharmacogenomic Variants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Pharmacogenomic screening plays a crucial role in optimizing chemotherapy outcomes and minimizing toxicity. Characterizing the baseline distribution of genetic variants in specific populations is essential to inform the prioritization of drug–gene combinations for clinical implementation. The objective of this study was to investigate the distribution of pharmacogenetic variants in 36 genes related to the fluoropyrimidine (FP) pathway among healthy Omani individuals, forming a foundation for future studies in cancer patients receiving FP-based chemotherapy.
Methods
Ninety-eight healthy Omani participants aged ≥18 years were recruited at the Sultan Qaboos Comprehensive Cancer Care and Research Center. Whole-blood samples were collected, and genomic DNA was extracted. Targeted next-generation sequencing was performed using a custom Ion AmpliSeq panel covering coding exons and splice-site regions of 36 genes involved in FP metabolism and response.
Results
A total of 999 variants were detected across the 36 genes, with 63.3% being heterozygous. The ABCC4 gene had the highest mutation frequency (76 mutations), while DHFR and SMUG1 had the lowest (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratories, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat 123, Oman.
- Clinical Trials Department, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat 123, Oman.
- Pharmacy Department, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat 123, Oman.
- Department of Medical Oncology, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat 123, Oman.
- Pharmacy Department, Omani National Hematology and Bone Marrow Transplant Center, University Medical City, Muscat 123, Oman.
ORCID-Profile: Shoaib Al-Zadjali, Aida Al-Kindy
Zitieren
APA
Al-Mahrouqi, N., Al Shuaili, N., Al-Zadjali, S., Pullanhi, A., Al-Barwani, H., Al-Kindy, A., Al-Sharqi, H., Al-Baimani, K., Al-Moundhri, M., & Salman, B. (2025). Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls. Genes, 16(5), 592. https://doi.org/10.3390/genes16050592
Vancouver
Al-Mahrouqi N, Al Shuaili N, Al-Zadjali S, Pullanhi A, Al-Barwani H, Al-Kindy A, et al. Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls. Genes. 2025;16(5):592. doi:10.3390/genes16050592
BibTeX
@article{AlMahrouqi2025,
author = {Al-Mahrouqi, Nahad and Al Shuaili, Nada and Al-Zadjali, Shoaib and Pullanhi, Anoopa and Al-Barwani, Hamida and Al-Kindy, Aida and Al-Sharqi, Hadeel and Al-Baimani, Khalid and Al-Moundhri, Mansour and Salman, Bushra},
title = {Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls},
journal = {Genes},
year = {2025},
volume = {16},
number = {5},
pages = {592},
doi = {10.3390/genes16050592}
}
EUVIMED